Dentsply Sirona (XRAY) shares plunged 5.07% on Friday following the company's Q4 2024 earnings report, which showed a wider net loss of $910 million and earnings per share of -$4.48 that missed analyst expectations. The dental equipment maker's revenue also declined 4.3% year-over-year.
In the wake of the weak results, several analysts downgraded their ratings and price targets on XRAY. Bank of America lowered its target to $19 citing limited visibility, while Wells Fargo cut its target to $19 as well citing the company's cost pressures. Barrington lowered its target but maintained an Outperform rating.
Analysts point to ongoing market challenges and headwinds impacting Dentsply Sirona's performance. The company is struggling with rising costs and competitive pressures in the dental equipment market. Looking ahead, slowing revenue growth forecasts suggest these issues could persist.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.